NCT01206296View on ClinicalTrials.gov

Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

Intraperitoneal Gemcitabine

"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"

Trial Locations (1)

20010

Washington Cancer Institute at MedStar Washington Hospital Center, Washington D.C.

Sponsors
All Listed Sponsors
lead

Medstar Health Research Institute

OTHER